Elevated Serum Sialyl Lewis X-i Antigen Levels in Non-Small Cell Lung Cancer with Lung Metastasis
Authors:
- Hiroaki SatohHSHiroaki Satoh
- Hiroichi IshikawaHIHiroichi Ishikawa
- Hiroshi KammaHKHiroshi Kamma
- Yuko T. YamashitaYYYuko T. Yamashita
- Hideto TakahashiHTHideto Takahashi
- Morio OhtsukaMOMorio Ohtsuka
- Shizuo HasegawaSHShizuo Hasegawa
- 1 August 1998
- journal article
- clinical trial
- Published by S. Karger AG in Respiration
- Vol. 65 (4) , 295-298
Abstract
To evaluate the relationship between serum levels of sialyl Lewis X-i antigen and lung metastasis in patients with non-small cell lung cancer (NSCLC), we measured the serum level of the antigen in 299 patients with untreated locally advanced or metastatic NSCLC. Before treatment, serum levels of sialyl Lewis X-i antigen were significantly higher in patients with lung metastasis than in those without lung metastatis (p = 0.0001). Of 201 patients without lung metastasis at the time of primary diagnosis, 121 patients died between July 1987 and December 1995. Serum levels of sialyl Lewis X-i antigen in 21 patients who developed lung metastasis during the period were significantly higher than those in 100 patients who did not develop lung metastasis (p = 0.0171). Our results suggested that sialyl Lewis X-i antigen might be a good indicator for the presence or development of lung metastasis, and it might provide clinical information about the management of patients with NSCLC.Keywords
This publication has 1 reference indexed in Scilit:
- Expression of Lewis-related antigen and prognosis in stage I non—small cell lung cancerThe Annals of Thoracic Surgery, 1995